Author:
Mollica Michelle A.,Zaleta Alexandra K.,Gallicchio Lisa,Brick Rachelle,Jacobsen Paul B.,Tonorezos Emily,Castro Kathleen M.,Miller Melissa F.
Funder
AbbVie
Amgen
AstraZeneca United States
Bristol-Myers Squibb
Celgene
Eli Lilly and Company
EMD Serono
Genentech
North Carolina GlaxoSmithKline Foundation
Janssen Pharmaceuticals
Jazz Pharmaceuticals Canada
Novartis Pharmaceuticals Corporation
Pfizer
Pharmacyclics
Seagen
Takeda Pharmaceuticals U.S.A.
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Abrams HR, Durbin S, Huang CX, Johnson SF, Nayak RK, Zahner GJ, Peppercorn J (2021) Financial toxicity in cancer care: origins, impact, and solutions. Transl Behav Med 11:2043–2054
2. Altice C (2017) BAnegas M, Tucker-Seeley R, Yabroff K. Financial hardships experiences by cancer survivors: a systematic review J Natl Cancer Inst 109:1–17
3. American Cancer Society (2022) Cancer facts & figures. American Cancer Society, Atlanta, GA
4. Carrera PM, Kantarjian HM, Blinder VS (2018) The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin 68:153–165
5. Chan K, Sepassi A, Saunders IM, Goodman A, Watanabe JH (2022) Effects of financial toxicity on prescription drug use and mental well-being in cancer patients. Explor Res Clin Soc Pharm 6:100136